reports
Imagion Biosystems Limited: 1 director
A director at Imagion Biosystems Limited maiden bought 500,000 shares at 0.081AUD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
- Sean Conroy
Imagion Biosystems - Nanoparticle-based imaging technology
Imagion Biosystems focuses on the development of new medical imaging techniques using magnetic nanoparticles to identify and diagnose cancer. The company aims to disrupt the cancer diagnosis market, which it estimates is worth US$100bn annually, with its non-invasive and non-radioactive MagSense imaging platform. Imagion’s technology is in Phase I trials for the detection of HER2 positive metastatic breast cancer. In 2019, the FDA awarded the MagSense platform Breakthrough Device status, offerin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.